Gossamer Bio, Inc. (GOSS)
NASDAQ: GOSS · Real-Time Price · USD
3.330
+0.010 (0.30%)
At close: Dec 5, 2025, 4:00 PM EST
3.300
-0.030 (-0.90%)
After-hours: Dec 5, 2025, 7:58 PM EST
Gossamer Bio Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Gossamer Bio stock have an average target of 8.60, with a low estimate of 5.00 and a high estimate of 11. The average target predicts an increase of 158.26% from the current stock price of 3.33.
Analyst Consensus: Strong Buy
* Price targets were last updated on Sep 10, 2025.
Analyst Ratings
The average analyst rating for Gossamer Bio stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 3 | 3 | 3 | 3 |
| Buy | 2 | 2 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Sep 11, 2025 |
| UBS | UBS | Hold → Strong Buy Upgrades $1.25 → $9 | Hold → Strong Buy | Upgrades | $1.25 → $9 | +170.27% | Sep 10, 2025 |
| Wedbush | Wedbush | Buy Maintains $4 → $5 | Buy | Maintains | $4 → $5 | +50.15% | Aug 6, 2025 |
| Scotiabank | Scotiabank | Buy Initiates $11 | Buy | Initiates | $11 | +230.33% | Jul 14, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $7 → $8 | Strong Buy | Maintains | $7 → $8 | +140.24% | May 16, 2025 |
Financial Forecast
Revenue This Year
43.04M
from 114.70M
Decreased by -62.48%
Revenue Next Year
45.79M
from 43.04M
Increased by 6.41%
EPS This Year
-0.73
from -0.25
EPS Next Year
-0.59
from -0.73
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 51.6M | 126.4M | ||||
| Avg | 43.0M | 45.8M | ||||
| Low | 34.0M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -55.0% | 193.8% | ||||
| Avg | -62.5% | 6.4% | ||||
| Low | -70.4% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -0.62 | -0.21 | ||||
| Avg | -0.73 | -0.59 | ||||
| Low | -0.78 | -0.98 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.